pmc-enju-pas Home  

PMC:3342329 / 19105-20096 JSONTXT 22 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T9412 0-2 IN denotes In
T9413 3-6 DT denotes the
T9414 7-14 JJ denotes present
T9415 15-20 NN denotes study
T9416 20-21 -COMMA- denotes ,
T9417 22-24 PRP denotes we
T9418 25-30 VB denotes found
T9419 31-35 IN denotes that
T9420 36-41 NN denotes tumor
T9421 42-48 NN denotes weight
T9422 49-52 CC denotes and
T9423 53-59 NN denotes volume
T9424 60-64 VB denotes were
T9425 65-69 RB denotes much
T9426 70-77 JJ denotes smaller
T9427 78-80 IN denotes in
T9428 81-84 DT denotes the
T9429 85-92 NN denotes CCR5−/−
T9430 93-97 NN denotes mice
T9431 98-106 VB denotes compared
T9432 107-109 TO denotes to
T9433 110-113 DT denotes the
T9434 114-121 JJ denotes CCR5+/+
T9435 122-126 NN denotes mice
T9436 127-137 VB denotes inoculated
T9437 138-142 IN denotes with
T9438 143-146 NN denotes B16
T9439 147-155 NN denotes melanoma
T9440 156-161 NN denotes cells
T9441 162-163 -LRB- denotes (
T9442 163-169 NN denotes Figure
T9443 170-172 NN denotes 1A
T9444 173-176 CC denotes and
T9445 177-179 NN denotes 1B
T9446 179-180 -RRB- denotes )
T9447 182-185 DT denotes The
T9448 186-191 NN denotes tumor
T9449 192-198 NN denotes growth
T9450 199-209 NN denotes inhibition
T9451 210-212 IN denotes in
T9452 213-216 DT denotes the
T9453 217-224 NN denotes CCR5−/−
T9454 225-229 NN denotes mice
T9455 230-233 VB denotes was
T9456 234-244 VB denotes associated
T9457 245-249 IN denotes with
T9458 250-253 DT denotes the
T9459 254-264 NN denotes inhibition
T9460 265-267 IN denotes of
T9461 268-282 RB denotes constitutively
T9462 283-292 VB denotes activated
T9463 293-298 NN denotes NF-κB
T9464 299-302 CC denotes and
T9465 303-312 NN denotes elevation
T9466 313-315 IN denotes of
T9467 316-322 NN denotes IL-1Ra
T9468 323-325 IN denotes in
T9469 326-329 DT denotes the
T9470 330-335 NN denotes tumor
T9471 336-342 NN denotes tissue
T9472 344-348 DT denotes This
T9473 349-359 JJ denotes anti-tumor
T9474 360-368 NN denotes activity
T9475 369-372 VB denotes was
T9476 373-377 RB denotes also
T9477 378-388 VB denotes associated
T9478 389-393 IN denotes with
T9479 394-403 VB denotes decreased
T9480 404-414 NN denotes expression
T9481 415-417 IN denotes of
T9482 418-423 NN denotes NF-κB
T9483 424-430 NN denotes target
T9484 431-445 JJ denotes anti-apoptotic
T9485 445-446 -COMMA- denotes ,
T9486 447-451 NN denotes cell
T9487 452-465 JJ denotes proliferative
T9488 465-466 -COMMA- denotes ,
T9489 467-470 CC denotes and
T9490 471-476 NN denotes tumor
T9491 477-486 VB denotes promoting
T9492 487-492 NN denotes genes
T9493 493-494 -LRB- denotes (
T9494 494-499 NN denotes Bcl-2
T9495 500-503 CC denotes and
T9496 504-510 NN denotes C-IAP1
T9497 510-511 -RRB- denotes )
T9498 512-515 CC denotes but
T9499 516-520 IN denotes with
T9500 521-530 VB denotes increased
T9501 531-541 NN denotes expression
T9502 542-544 IN denotes of
T9503 545-550 PRP-DOLLAR- denotes their
T9504 551-557 NN denotes target
T9505 558-567 JJ denotes apoptotic
T9506 568-573 NN denotes genes
T9507 573-574 -COLON- denotes ;
T9508 575-582 VB denotes cleaved
T9509 583-592 NN denotes caspase-3
T9510 593-596 CC denotes and
T9511 597-598 CD denotes 9
T9512 598-599 -COMMA- denotes ,
T9513 600-603 CC denotes and
T9514 604-607 NN denotes Bax
T9515 608-609 -LRB- denotes (
T9516 609-615 NN denotes Figure
T9517 616-620 NN denotes 3A-D
T9518 620-621 -RRB- denotes )
T9519 623-625 IN denotes In
T9520 626-629 DT denotes the
T9521 630-635 NN denotes tumor
T9522 636-639 CC denotes and
T9523 640-643 DT denotes the
T9524 644-650 NN denotes spleen
T9525 650-651 -COMMA- denotes ,
T9526 652-655 DT denotes the
T9527 656-662 NN denotes number
T9528 663-665 IN denotes of
T9529 666-675 JJ denotes cytotoxic
T9530 676-680 JJ denotes CD8+
T9531 681-682 NN denotes T
T9532 683-688 NN denotes cells
T9533 688-689 -COMMA- denotes ,
T9534 690-695 JJ denotes CD57+
T9535 696-703 JJ denotes natural
T9536 704-710 NN denotes killer
T9537 711-716 NN denotes cells
T9538 716-717 -COMMA- denotes ,
T9539 718-721 CC denotes and
T9540 722-725 DT denotes the
T9541 726-732 NN denotes levels
T9542 733-735 IN denotes of
T9543 736-742 NN denotes IL-1Ra
T9544 743-747 VB denotes were
T9545 748-757 VB denotes increased
T9546 758-759 -LRB- denotes (
T9547 759-765 NN denotes Figure
T9548 766-767 CD denotes 4
T9549 768-771 CC denotes and
T9550 772-773 CD denotes 5
T9551 773-774 -RRB- denotes )
T9552 776-781 DT denotes These
T9553 782-790 NN denotes findings
T9554 791-798 VB denotes suggest
T9555 799-803 IN denotes that
T9556 804-812 NN denotes melanoma
T9557 813-819 NN denotes growth
T9558 820-823 VB denotes was
T9559 824-833 VB denotes inhibited
T9560 834-836 IN denotes in
T9561 837-840 DT denotes the
T9562 841-848 NN denotes CCR5−/−
T9563 849-853 NN denotes mice
T9564 853-854 -COMMA- denotes ,
T9565 855-858 CC denotes and
T9566 859-863 IN denotes that
T9567 864-867 DT denotes the
T9568 868-877 NN denotes elevation
T9569 878-880 IN denotes of
T9570 881-887 NN denotes IL-1Ra
T9571 887-888 -COMMA- denotes ,
T9572 889-900 VB denotes accompanied
T9573 901-905 IN denotes with
T9574 906-915 VB denotes decreased
T9575 916-921 NN denotes NF-κB
T9576 921-922 -COMMA- denotes ,
T9577 923-925 VB denotes is
T9578 926-937 JJ denotes significant
T9579 938-940 IN denotes in
T9580 941-944 DT denotes the
T9581 945-955 NN denotes inhibition
T9582 956-958 IN denotes of
T9583 959-967 NN denotes melanoma
T9584 968-974 NN denotes growth
T9585 975-977 IN denotes in
T9586 978-985 NN denotes CCR5−/−
T9587 986-990 NN denotes mice
R5958 T9415 T9412 arg2Of study,In
R5959 T9415 T9413 arg1Of study,the
R5960 T9415 T9414 arg1Of study,present
R5961 T9417 T9418 arg1Of we,found
R5962 T9418 T9412 arg1Of found,In
R5963 T9418 T9416 arg1Of found,","
R5964 T9421 T9420 arg1Of weight,tumor
R5965 T9421 T9422 arg1Of weight,and
R5966 T9422 T9424 arg1Of and,were
R5967 T9422 T9426 arg1Of and,smaller
R5968 T9423 T9422 arg2Of volume,and
R5969 T9424 T9418 arg2Of were,found
R5970 T9424 T9419 arg1Of were,that
R5971 T9424 T9427 arg1Of were,in
R5972 T9424 T9431 arg1Of were,compared
R5973 T9426 T9424 arg2Of smaller,were
R5974 T9426 T9425 arg1Of smaller,much
R5975 T9430 T9427 arg2Of mice,in
R5976 T9430 T9428 arg1Of mice,the
R5977 T9430 T9429 arg1Of mice,CCR5−/−
R5978 T9432 T9431 arg2Of to,compared
R5979 T9435 T9432 arg2Of mice,to
R5980 T9435 T9433 arg1Of mice,the
R5981 T9435 T9434 arg1Of mice,CCR5+/+
R5982 T9435 T9436 arg2Of mice,inoculated
R5983 T9436 T9437 arg1Of inoculated,with
R5984 T9440 T9437 arg2Of cells,with
R5985 T9440 T9438 arg1Of cells,B16
R5986 T9440 T9439 arg1Of cells,melanoma
R5987 T9440 T9441 arg1Of cells,(
R5988 T9443 T9442 arg1Of 1A,Figure
R5989 T9443 T9444 arg1Of 1A,and
R5990 T9444 T9441 arg2Of and,(
R5991 T9445 T9444 arg2Of 1B,and
R5992 T9446 T9441 arg3Of ),(
R5993 T9450 T9447 arg1Of inhibition,The
R5994 T9450 T9448 arg1Of inhibition,tumor
R5995 T9450 T9449 arg1Of inhibition,growth
R5996 T9450 T9451 arg1Of inhibition,in
R5997 T9450 T9455 arg1Of inhibition,was
R5998 T9450 T9456 arg2Of inhibition,associated
R5999 T9454 T9451 arg2Of mice,in
R6000 T9454 T9452 arg1Of mice,the
R6001 T9454 T9453 arg1Of mice,CCR5−/−
R6002 T9456 T9455 arg2Of associated,was
R6003 T9456 T9457 arg1Of associated,with
R6004 T9459 T9457 arg2Of inhibition,with
R6005 T9459 T9458 arg1Of inhibition,the
R6006 T9459 T9460 arg1Of inhibition,of
R6007 T9463 T9462 arg2Of NF-κB,activated
R6008 T9463 T9464 arg1Of NF-κB,and
R6009 T9464 T9460 arg2Of and,of
R6010 T9464 T9461 arg1Of and,constitutively
R6011 T9464 T9468 arg1Of and,in
R6012 T9465 T9464 arg2Of elevation,and
R6013 T9465 T9466 arg1Of elevation,of
R6014 T9467 T9466 arg2Of IL-1Ra,of
R6015 T9471 T9468 arg2Of tissue,in
R6016 T9471 T9469 arg1Of tissue,the
R6017 T9471 T9470 arg1Of tissue,tumor
R6018 T9474 T9472 arg1Of activity,This
R6019 T9474 T9473 arg1Of activity,anti-tumor
R6020 T9474 T9475 arg1Of activity,was
R6021 T9474 T9477 arg2Of activity,associated
R6022 T9474 T9508 arg1Of activity,cleaved
R6023 T9477 T9475 arg2Of associated,was
R6024 T9477 T9476 arg1Of associated,also
R6025 T9477 T9478 arg1Of associated,with
R6026 T9477 T9499 arg1Of associated,with
R6027 T9477 T9507 arg1Of associated,;
R6028 T9478 T9498 arg1Of with,but
R6029 T9480 T9479 arg2Of expression,decreased
R6030 T9480 T9481 arg1Of expression,of
R6031 T9480 T9489 arg1Of expression,and
R6032 T9483 T9481 arg2Of target,of
R6033 T9483 T9482 arg1Of target,NF-κB
R6034 T9483 T9484 arg1Of target,anti-apoptotic
R6035 T9483 T9487 arg1Of target,proliferative
R6036 T9484 T9485 arg1Of anti-apoptotic,","
R6037 T9487 T9485 arg2Of proliferative,","
R6038 T9487 T9486 arg1Of proliferative,cell
R6039 T9489 T9478 arg2Of and,with
R6040 T9489 T9488 arg1Of and,","
R6041 T9490 T9489 arg2Of tumor,and
R6042 T9490 T9491 arg1Of tumor,promoting
R6043 T9492 T9491 arg2Of genes,promoting
R6044 T9492 T9493 arg1Of genes,(
R6045 T9494 T9495 arg1Of Bcl-2,and
R6046 T9495 T9493 arg2Of and,(
R6047 T9496 T9495 arg2Of C-IAP1,and
R6048 T9497 T9493 arg3Of ),(
R6049 T9499 T9498 arg2Of with,but
R6050 T9501 T9499 arg2Of expression,with
R6051 T9501 T9500 arg2Of expression,increased
R6052 T9501 T9502 arg1Of expression,of
R6053 T9506 T9502 arg2Of genes,of
R6054 T9506 T9503 arg1Of genes,their
R6055 T9506 T9504 arg1Of genes,target
R6056 T9506 T9505 arg1Of genes,apoptotic
R6057 T9508 T9507 arg2Of cleaved,;
R6058 T9509 T9510 arg1Of caspase-3,and
R6059 T9510 T9513 arg1Of and,and
R6060 T9511 T9510 arg2Of 9,and
R6061 T9513 T9508 arg2Of and,cleaved
R6062 T9513 T9512 arg1Of and,","
R6063 T9514 T9513 arg2Of Bax,and
R6064 T9514 T9515 arg1Of Bax,(
R6065 T9517 T9515 arg2Of 3A-D,(
R6066 T9517 T9516 arg1Of 3A-D,Figure
R6067 T9518 T9515 arg3Of ),(
R6068 T9521 T9520 arg1Of tumor,the
R6069 T9521 T9522 arg1Of tumor,and
R6070 T9522 T9519 arg2Of and,In
R6071 T9524 T9522 arg2Of spleen,and
R6072 T9524 T9523 arg1Of spleen,the
R6073 T9527 T9526 arg1Of number,the
R6074 T9527 T9528 arg1Of number,of
R6075 T9527 T9533 arg1Of number,","
R6076 T9532 T9528 arg2Of cells,of
R6077 T9532 T9529 arg1Of cells,cytotoxic
R6078 T9532 T9530 arg1Of cells,CD8+
R6079 T9532 T9531 arg1Of cells,T
R6080 T9533 T9539 arg1Of ",",and
R6081 T9537 T9533 arg2Of cells,","
R6082 T9537 T9534 arg1Of cells,CD57+
R6083 T9537 T9535 arg1Of cells,natural
R6084 T9537 T9536 arg1Of cells,killer
R6085 T9539 T9538 arg1Of and,","
R6086 T9539 T9544 arg1Of and,were
R6087 T9539 T9545 arg2Of and,increased
R6088 T9541 T9539 arg2Of levels,and
R6089 T9541 T9540 arg1Of levels,the
R6090 T9541 T9542 arg1Of levels,of
R6091 T9543 T9542 arg2Of IL-1Ra,of
R6092 T9545 T9519 arg1Of increased,In
R6093 T9545 T9525 arg1Of increased,","
R6094 T9545 T9544 arg2Of increased,were
R6095 T9545 T9546 arg1Of increased,(
R6096 T9547 T9548 arg1Of Figure,4
R6097 T9547 T9549 arg1Of Figure,and
R6098 T9549 T9546 arg2Of and,(
R6099 T9550 T9549 arg2Of 5,and
R6100 T9551 T9546 arg3Of ),(
R6101 T9553 T9552 arg1Of findings,These
R6102 T9553 T9554 arg1Of findings,suggest
R6103 T9557 T9556 arg1Of growth,melanoma
R6104 T9557 T9558 arg1Of growth,was
R6105 T9557 T9559 arg2Of growth,inhibited
R6106 T9559 T9555 arg1Of inhibited,that
R6107 T9559 T9558 arg2Of inhibited,was
R6108 T9559 T9560 arg1Of inhibited,in
R6109 T9559 T9565 arg1Of inhibited,and
R6110 T9563 T9560 arg2Of mice,in
R6111 T9563 T9561 arg1Of mice,the
R6112 T9563 T9562 arg1Of mice,CCR5−/−
R6113 T9565 T9554 arg2Of and,suggest
R6114 T9565 T9564 arg1Of and,","
R6115 T9566 T9565 arg2Of that,and
R6116 T9568 T9567 arg1Of elevation,the
R6117 T9568 T9569 arg1Of elevation,of
R6118 T9568 T9571 arg1Of elevation,","
R6119 T9568 T9572 arg2Of elevation,accompanied
R6120 T9568 T9577 arg1Of elevation,is
R6121 T9568 T9578 arg1Of elevation,significant
R6122 T9570 T9569 arg2Of IL-1Ra,of
R6123 T9572 T9573 arg1Of accompanied,with
R6124 T9575 T9573 arg2Of NF-κB,with
R6125 T9575 T9574 arg2Of NF-κB,decreased
R6126 T9577 T9566 arg2Of is,that
R6127 T9577 T9576 arg1Of is,","
R6128 T9578 T9577 arg2Of significant,is
R6129 T9578 T9579 arg1Of significant,in
R6130 T9581 T9579 arg2Of inhibition,in
R6131 T9581 T9580 arg1Of inhibition,the
R6132 T9581 T9582 arg1Of inhibition,of
R6133 T9584 T9582 arg2Of growth,of
R6134 T9584 T9583 arg1Of growth,melanoma
R6135 T9584 T9585 arg1Of growth,in
R6136 T9587 T9585 arg2Of mice,in
R6137 T9587 T9586 arg1Of mice,CCR5−/−